Hot Products

Columbianetin beta-D-glucopyranoside
Catalog No: CFN95038

Columbianetin-beta-D-glucopyranoside exhibits anti-inflammatory and analgesic properties, it also shows strong inhibiting activity against platelet aggregation.

Columbin
Catalog No: CFN90480

Columbin has anti-inflammation activity, it has chemopreventive ability against human colon cancer, it also can inhibit growth of culture forms of Trypanosoma brucei. Columbin inhibits PLA2 hydrolysis of ghost RBC in a dose-dependent fashion.

Colupulone
Catalog No: CFN91873

Colupulone is an inducer of hepatic cytochrome P-4503A .Colupulone can increase cytochrome P450IIB and P450IIIA steady-state mRNA levels. Colupulone also has antibacterial effects.

Colutehydroquinone
Catalog No: CFN91022

Colutehydroquinone and colutequinone are antifungal isoflavonoids from Colutea arborescens.

Communic acid
Catalog No: CFN98332

Communic acid has antibacterial activity, including against mycobacterial. trans-Communic acid has potential to be utilized as anti-wrinkling agents and cosmetic ingredients, as they suppress UVB-induced MMP-1 expression.

Complanatoside
Catalog No: CFN91011

Complanatoside C is a natural product from Astragali Semen.

Complanatoside A
Catalog No: CFN99525

Complanatoside A is a flavonol glycoside isolated from Astragalus complanatus, and currently it is used as a quality control index for A. complanatus in the 2010 edition of the Chinese Pharmacopoeia.

Complanatoside B
Catalog No: CFN80156

Reference standards.

Conduritol A
Catalog No: CFN98868

Conduritol A has a hypoglycemic effect, can have an effect on regulating the metabolism of blood lipid, free-radical scavenging, enhancing the antioxidant ability, potentiating immune function; it also can markedly prevent the diabetic rats from getting cataracts through the inhibition of lens aldose reductase.

Conessine
Catalog No: CFN70405

Conessine as a novel inhibitor of multidrug efflux pump systems in Pseudomonas aeruginosa, it shows antibacterial, antifeedant, and anti-malarial effects. Conessine treatment reduces dexamethasone-induced muscle atrophy by regulating MuRF1 and atrogin-1 expression